Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Biotech and technology weighed on the Nasdaq composite, knocking stocks sharply lower Monday afternoon, while losses in Merck and other blue chips overshadowed 3M's improved forecast among Dow Jones ...

NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in southern India, with additional investments anticipated, CEO Robert ...

The product is manufactured by Immunex Corp and marketed by Amgen and Wyeth Pharmaceuticals. Enbrel is also approved to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic ...

US drug major Amgen on Monday announced the opening of its new technology and innovation site in Hyderabad. The company said it plans to invest $200 million through 2025, with additional ...

Som Chattopadhyay, national executive India, Amgen, said the first 300 employees were hired within 78 days of signing the contract for the new facility and another 300 are to be onboarded soon ...

HYDERABAD, India (Reuters) - U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said ...

Reuters is an international news organisation owned by Thomson Reuters US drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ ... to acquire California-based Carmot Therapeutics. The corporation wants to “fast-track” its anti-obesity medicines ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.